1. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2. Thatcher N, Chang A, Parikh P, et al: ISEL: A phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens. Lung Cancer 49:S4,2005, (abstr Pr4)
3. Kim ES, Mauer AM, Tran HT, et al: A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report. Proc Am Soc Clin Oncol 22:642s,2003, (abstr 2581)
4. Kelly K, Hanna N, Rosenberg A, et al: A multi-center phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 22:644s,2003, (abstr 2592)